Compare Stocks: CVRS, TMDX, PLSE, and AXGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$48.73 +1.4%	$43.42	$13.64 ▼ $49.93	$2.62B	1.11	1.07 million shs	632,310 shs
CVRS Corindus Vascular Robotics	$4.27	$4.27	$0.78 ▼ $4.40	$891.09M	N/A	1.99 million shs	N/A
PLSE Pulse Biosciences	$44.54 -0.8%	$30.86	$12.56 ▼ $46.97	$3.08B	1.61	448,783 shs	401,178 shs
TMDX TransMedics Group	$88.58 -1.2%	$75.65	$60.10 ▼ $156.00	$3.06B	1.9	1.03 million shs	433,861 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	+1.42%	+4.95%	+25.85%	+18.88%	+230.15%
CVRS Corindus Vascular Robotics	0.00%	0.00%	0.00%	0.00%	0.00%
PLSE Pulse Biosciences	-0.85%	+5.02%	+69.22%	+81.43%	+165.28%
TMDX TransMedics Group	-1.18%	+5.59%	+17.51%	+40.16%	-32.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$48.73 +1.4%	$43.42	$13.64 ▼ $49.93	$2.62B	1.11	1.07 million shs	632,310 shs
CVRS Corindus Vascular Robotics	$4.27	$4.27	$0.78 ▼ $4.40	$891.09M	N/A	1.99 million shs	N/A
PLSE Pulse Biosciences	$44.54 -0.8%	$30.86	$12.56 ▼ $46.97	$3.08B	1.61	448,783 shs	401,178 shs
TMDX TransMedics Group	$88.58 -1.2%	$75.65	$60.10 ▼ $156.00	$3.06B	1.9	1.03 million shs	433,861 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	+1.42%	+4.95%	+25.85%	+18.88%	+230.15%
CVRS Corindus Vascular Robotics	0.00%	0.00%	0.00%	0.00%	0.00%
PLSE Pulse Biosciences	-0.85%	+5.02%	+69.22%	+81.43%	+165.28%
TMDX TransMedics Group	-1.18%	+5.59%	+17.51%	+40.16%	-32.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	2.73	Moderate Buy	$51.00	4.66% Upside
CVRS Corindus Vascular Robotics	0.00	N/A	N/A	N/A
PLSE Pulse Biosciences	2.50	Moderate Buy	$41.00	-7.95% Downside
TMDX TransMedics Group	2.38	Hold	$124.18	40.19% Upside

Current Analyst Ratings Breakdown

Latest CVRS, TMDX, PLSE, and AXGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	PLSE Pulse Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$45.00
8/10/2026	PLSE Pulse Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $43.00
8/5/2026	TMDX TransMedics Group	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $77.00
8/5/2026	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$120.00 ➝ $100.00
8/3/2026	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$142.00 ➝ $106.00
7/30/2026	AXGN AxoGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $53.00
7/30/2026	AXGN AxoGen	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/30/2026	AXGN AxoGen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
7/30/2026	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
7/30/2026	AXGN AxoGen	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$50.00 ➝ $55.00
7/29/2026	AXGN AxoGen	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$225.21M	11.63	N/A	N/A	$4.77 per share	10.22
CVRS Corindus Vascular Robotics	N/A	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	$350K	8,807.47	N/A	N/A	$1.44 per share	30.93
TMDX TransMedics Group	$605.49M	5.06	$3.93 per share	22.56	$14.99 per share	5.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$15.70M	-$0.68	N/A	974.60	N/A	-13.36%	-8.90%	-6.47%	N/A
CVRS Corindus Vascular Robotics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	-$72.78M	-$1.18	N/A	N/A	N/A	-6,755.78%	-94.42%	-79.96%	N/A
TMDX TransMedics Group	$190.29M	$3.89	22.77	38.18	N/A	22.69%	15.88%	5.95%	N/A

Latest CVRS, TMDX, PLSE, and AXGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	-$0.36	-$0.0667	-$0.36	$0.53 million	$0.43 million
8/4/2026	Q2 2026	TMDX TransMedics Group	$0.4955	$0.44	-$0.0555	$0.41	$184.00 million	$189.95 million
7/29/2026	Q2 2026	AXGN AxoGen	$0.1214	$0.12	-$0.0014	-$0.03	$67.10 million	$69.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
CVRS Corindus Vascular Robotics	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.07	6.60	5.04
CVRS Corindus Vascular Robotics	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	9.63	7.24
TMDX TransMedics Group	1.62	6.62	6.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
CVRS Corindus Vascular Robotics	N/A
PLSE Pulse Biosciences	76.95%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.44%
CVRS Corindus Vascular Robotics	N/A
PLSE Pulse Biosciences	74.00%
TMDX TransMedics Group	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	53.76 million	52.45 million	Optionable
CVRS Corindus Vascular Robotics	90	208.69 million	N/A	Not Optionable
PLSE Pulse Biosciences	140	69.21 million	18.00 million	Optionable
TMDX TransMedics Group	210	34.56 million	32.18 million	Optionable

CVRS, TMDX, PLSE, and AXGN Headlines

Recent News About These Companies

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

August 13 at 8:50 PM | globenewswire.com

Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX

August 13 at 5:21 AM | marketbeat.com

TransMedics (TMDX) Q2 2026 Earnings Call Transcript

August 12 at 7:04 PM | finance.yahoo.com

TransMedics Group, Inc. (TMDX) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

August 11, 2026 | seekingalpha.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

August 11, 2026 | prnewswire.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

August 8, 2026 | globenewswire.com

Piper Sandler Reaffirms Overweight Rating for TransMedics Group (NASDAQ:TMDX)

August 7, 2026 | americanbankingnews.com

TransMedics Group (NASDAQ:TMDX) Shares Gap Down Following Weak Earnings

August 7, 2026 | americanbankingnews.com

TransMedics: Margins Down, Concentration Up, Trials Delayed

August 6, 2026 | seekingalpha.com

TransMedics outlines $737M-$757M 2026 revenue outlook while targeting 30,000 transplants by 2032

August 5, 2026 | seekingalpha.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

August 5, 2026 | prnewswire.com

Piper Sandler Keeps Their Buy Rating on TransMedics Group (TMDX)

August 5, 2026 | theglobeandmail.com

TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $77.00 at UBS Group

August 5, 2026 | marketbeat.com

TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract

August 5, 2026 | zacks.com

TransMedics Group (NASDAQ:TMDX) Earns "Overweight" Rating from Piper Sandler

August 5, 2026 | marketbeat.com

TransMedics Group (NASDAQ:TMDX) Shares Gap Down on Disappointing Earnings

August 5, 2026 | marketbeat.com

TransMedics Group, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Needham & Company LLC Issues Pessimistic Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

August 5, 2026 | americanbankingnews.com

TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

TransMedics Group Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say

August 4, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRS, TMDX, PLSE, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

$48.73 +0.68 (+1.42%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$48.73 0.00 (0.00%)

As of 08/14/2026 07:34 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Corindus Vascular Robotics NYSEAMERICAN:CVRS

$4.27 0.00 (0.00%)

As of 11/27/2019

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.

Pulse Biosciences NASDAQ:PLSE

$44.54 -0.38 (-0.85%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$44.77 +0.23 (+0.53%)

As of 08/14/2026 07:37 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

TransMedics Group NASDAQ:TMDX

$88.58 -1.06 (-1.18%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$88.42 -0.16 (-0.18%)

As of 08/14/2026 07:58 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVRS, TMDX, PLSE, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVRS, TMDX, PLSE, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVRS, TMDX, PLSE, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRS, TMDX, PLSE, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

Corindus Vascular Robotics NYSEAMERICAN:CVRS

Pulse Biosciences NASDAQ:PLSE

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVRS, TMDX, PLSE, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVRS, TMDX, PLSE, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVRS, TMDX, PLSE, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRS, TMDX, PLSE, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

Corindus Vascular Robotics NYSEAMERICAN:CVRS

Pulse Biosciences NASDAQ:PLSE

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools